Announcements
On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc


In this issue


Home Eurosurveillance Weekly Release  2002: Volume 6/ Issue 12 Article 2
Back to Table of Contents
Previous
Next

Eurosurveillance, Volume 6, Issue 12, 21 March 2002
Articles

Citation style for this article: Løvoll Ø, Sandbu S. Measles and measles immunisation in Norway: historical review and present situation. Euro Surveill. 2002;6(12):pii=2099. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2099

Measles and measles immunisation in Norway: historical review and present situation

Notification of measles has been mandatory in Norway since 1975, when the Meldesystem for smittsomme sykdommer (MSIS, notification system) was implemented nationally (1). Since 1988, measles cases have been notified individually by name, based on laboratory confirmation or an epidemiological link to a laboratory confirmed case.

Measles vaccine was introduced in 1969 with a single dose at the age of 12 months. The measles, mumps, and rubella (MMR) vaccine was introduced in 1983 as a two dose programme (at 15 months and 13 years).
Between 1969 and 1983, measles vaccination coverage was 70-80%. Since the introduction of MMR in 1983, national coverage has been 90-95% for both doses. A third dose of MMR has been included in the programme for new military recruits (the vast majority of whom are male) since 1999, to prevent outbreaks in military camps.

Seroepidemiological surveys have shown that more than 97% of Norwegians born before the introduction of measles immunisation in 1969 had contracted measles. This confirms the assumption that almost all children in Norway contracted measles before the vaccine was introduced.

Before 1969, measles typically appeared in epidemics every three years. The annual number of notified cases has been dropping gradually since the mid-1970s, and since 1990, the annual figures have been below 20, except in 1990 (95 cases), 1992 (73 cases), and 1996 (23 cases). All these cases were laboratory confirmed or linked to laboratory confirmed cases.

The most recent outbreak was in Nesodden, a municipality outside Oslo, at the end of 1996. Fourteen cases were reported to MSIS, and the local health authority registered a total of 82 cases. Most of the patients had refused vaccination for reasons of personal conviction, and only three had been immunised against measles. The disease was probably brought to Nesodden by two unvaccinated children who had been exposed to measles while visiting Switzerland.

Eight cases have been reported between 1998 and 2001. Six patients contracted the disease outside Norway (in Mongolia, Pakistan, and Sri Lanka), and one was a secondary case. The other case, which had no known link with a source outside Norway, was reported in 1999.

These figures indicate that measles is no longer endemic in Norway.

Table. Number of measles cases and deaths from measles reported in 10 year periods 1931-2000. Source: MSIS and Statistics Norway

10 year period Reported cases Deaths
1931-40 105 430 345
1941-50 164 275 315
1951-60 218 660 115
1961-70 196 895 30
1971-80 112 985 22
1981-90 26 855 4
1991-00 159 0

The numbers of reported cases and deaths in the table should be interpreted with care as substantial underreporting of cases is probable, particularly in the pre-vaccine era when practically all children contracted measles. Cases reported since 1988 are laboratory confirmed, but cases reported before 1988 were based mainly on clinical diagnoses. The numbers of deaths must be considered minimum numbers as mortality statistics are based on the primary diagnosis on the death certificate, and cases where measles were a contributing cause of death will not be included.

Cases of encephalitis due to measles have been notified individually since 1975. Up to 2002 a total of 23 cases have been reported to MSIS, the last case being in 1994.

MSIS receives between 50 and 90 notifications annually of adverse events after MMR vaccination. Of these, fewer than 10 are classified as severe adverse events (allergic reactions, febrile seizures leading to hospitalisation and thrombocytopenia). There have been no deaths related to MMR or measles immunisation in Norway.

Some local health authorities are reporting growing concern among parents about MMR and autism, and are requesting monovalent vaccines. Extensive studies have shown no link (2,3). The Nasjonalt folkehelseinstitutt (Norwegian Institute of Public Health, NIPH) recommends MMR as the safest and best-studied vaccine. As the vaccine supplier for the national immunisation programme in Norway, NIPH make efforts to provide monovalent vaccines for those who demand it. It has, however, proved difficult to get such vaccines.

References :
  1. Løvoll O, Sandbu S. Meslingesituasjonen I Norge. MSIS-rapport 2002; 30(10). (http://www.folkehelsa.no/nyhetsbrev/msis/2002/10/msis1002a.html).
  2. Institute of Medicine (US). Immunization Safety Review: Measles-mumps-rubella vaccine and autism. Washington: National Academy Press; 2001.
  3. Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Meales, mumps and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324: 393-6. (http://bmj.com/cgi/reprint/324/7334/393.pdf)

Reported by Øistein Løvoll (oistein.lovoll@fhi.no) and Synne Sandbu, Nasjonalt folkehelseinstitutt (Norwegian Institute of Public Health), Oslo, Norway.

back to top



Back to Table of Contents
Previous
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.